DBCO-(PEG2-VC-PAB-MMAE)2 is a complex chemical compound that features a combination of various functional groups and polymeric components. The structure includes a dibenzocyclooctyne (DBCO) moiety, which is known for its bioorthogonal reactivity, particularly in click chemistry applications. The PEG (polyethylene glycol) segments provide solubility and biocompatibility, making the compound suitable for biological applications. The VC (vinyl carbamate) and PAB (p-aminobenzyl) groups are likely involved in conjugation or drug delivery mechanisms, while MMAE (monomethyl auristatin E) is a potent cytotoxic agent used in antibody-drug conjugates for targeted cancer therapy. Overall, this compound is characterized by its potential use in targeted drug delivery systems, leveraging the unique properties of its components to enhance therapeutic efficacy while minimizing off-target effects. Its design reflects a trend in medicinal chemistry aimed at improving the specificity and effectiveness of cancer treatments through advanced conjugation strategies.

DBCO-(PEG2-VC-PAB-MMAE)2

2259318-55-1: DBCO-(PEG2-VC-PAB-MMAE)2 is a complex chemical compound that features a combination of various functional groups and polymeric components. The structure includes a dibenzocyclooctyne (DBCO) moiety, which is known for its bioorthogonal reactivity, particularly in click chemistry applications. The PEG (polyethylene glycol) segments provide solubility and biocompatibility, making the compound suitable for biological applications. The VC (vinyl carbamate) and PAB (p-aminobenzyl) groups are likely involved in conjugation or drug delivery mechanisms, while MMAE (monomethyl auristatin E) is a potent cytotoxic agent used in antibody-drug conjugates for targeted cancer therapy. Overall, this compound is characterized by its potential use in targeted drug delivery systems, leveraging the unique properties of its components to enhance therapeutic efficacy while minimizing off-target effects. Its design reflects a trend in medicinal chemistry aimed at improving the specificity and effectiveness of cancer treatments through advanced conjugation strategies.

<p>DBCO-linked bispecific MMAE payload; potent tubulin inhibitor for antibody drug conjugates.</p>

CAS 2259318-55-1

DBCO-(PEG2-VC-PAB-MMAE)2

DBCO-(PEG2-VC-PAB-MMAE)2

Ref: TM-T17789